All Articles
Showing 109–120 of 155 articles.
FDA Clarifies Regulatory Expectations for AI-Driven Digital Wellness Interventions
FDA Clarifies Regulatory Expectations for AI-Driven Digital Wellness Interventions
Read More →What Primary Sources Show About Wearables in Men's Heart Health Prevention
What Primary Sources Show About Wearables in Men's Heart Health Prevention
Read More →FDA Warns of Undeclared PDE5 Inhibitors in OTC Male Enhancement Products
FDA Warns of Undeclared PDE5 Inhibitors in OTC Male Enhancement Products
Read More →What Pooled Trial Data Show About Digital Fitness Trackers and Men's Heart Health
What Pooled Trial Data Show About Digital Fitness Trackers and Men's Heart Health
Read More →How the FDA Classifies and Reviews Digital Tools for Wellness Tracking
How the FDA Classifies and Reviews Digital Tools for Wellness Tracking
Read More →Q&A: Current Uspstf Guidance on PSA-Based Prostate Cancer Screening for Men
Q&A: USPSTF Guidance on PSA-Based Prostate Cancer Screening for Men
Read More →FDA Revises Labeling and Monitoring Guidance for GLP-1 Drugs Used in Type 2 Diabetes and Weight Management
FDA Updates Postmarket Safety Monitoring Requirements for GLP-1 Receptor Agonists
Read More →What Peer-Reviewed Literature Says About Consumer Wearables and Heart Health Metrics in Male Populations
Recent PMC Studies Evaluate Wearable Devices for Cardiovascular Risk Monitoring in Men
Read More →Large-Scale Analyses Associate Higher Physical Activity Levels with Lower Mortality in Men
Large-Scale Analyses Associate Higher Physical Activity Levels With Lower Mortality in Men
Read More →FDA Mandates Revised Cardiovascular and Prostate Cancer Risk Information in Testosterone Therapy Labeling
FDA Requires Updated Safety Labeling for Testosterone Replacement Therapy Products
Read More →FDA Outlines Regulatory Framework for AI Tools Used in Preventive Cardiac Monitoring
FDA Outlines Regulatory Framework for AI Tools Used in Preventive Cardiac Monitoring
Read More →FDA Highlights Post-Approval Cardiovascular and Gastrointestinal Data for Semaglutide
FDA Highlights Post-Approval Cardiovascular and Gastrointestinal Data for Semaglutide
Read More →